MyMD Pharmaceuticals Inc

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

QCLS$0.37+8.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Comprehensive Loss

	For the Years Ended December 31,
	2023	2022
Product Revenue · $ · - · $ · -
Product Cost of Sales	-	-
Gross Income	-	-
Administrative Expenses	5,442,886	5,520,150
Research and Development Expenses	7,867,795	9,067,422
Stock Based Compensation	3,049,537	695,191
Warrant Issuance Expenses	762,834	-
Loss from Operations	(17,123,052)	(15,282,763)
Other (Income) Expenses
Interest and Dividend Income	(455,570)	(83,991)
(Gain)/Loss on Sales of Marketable Securities	(416)	5,964
Unrealized (Gain)/Loss on Marketable Securities	(514)	(2,958)
Change in fair value of Derivatives Liabilities	(3,088,800)	-
Change in fair value of Warrant Liabilities	(9,756,000)	-
Uninsured Casualty Losses	178,198	(4,442)
Total Other (Income) Expenses	(13,123,102)	(85,427)
Loss Before Income Tax	(3,999,950)	(15,197,336)
Income Tax Benefit	-	-
Net Loss	$(3,999,950)	$(15,197,336)
Preferred Stock Dividends	4,218,213	-
Net Income/(Loss) Attributable to Common Stockholders	$(8,218,163)	$(15,197,336)
Basic and Dilutive net loss per common share	$(5.33)	$(11.74)
Weighted average basic and diluted common shares outstanding	1,542,453	1,294,200

The accompanying notes are an integral part to these consolidated financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.